Is Celgene Really Overvalued?

High-profile analysts are worrying over Celgene's share price, but a strong pipeline suggests a bright future for the company.

Jan 6, 2014 at 2:13PM

Goldman Sachs resumed coverage of Celgene (NASDAQ:CELG) in December 2012 with a rating of "neutral" and a price target of $77 when shares were $81. In the wake of a near doubling since, the investment bank has now dropped its rating to "sell" from "neutral," knocking shares in Celgene down 5% on Monday.

But Celgene doesn't appear overpriced versus its peers, suggesting that investors may want to stay focused on the company's long-term potential rather than the short-term whims and whispers of these Wall Street analysts.

Building a cancer-killing franchise
Celgene is building an oncology powerhouse behind its blockbuster drug Revlimid, a treatment that won approval for myelodysplastic syndromes in 2005, multiple myeloma in 2006, and mantle cell lymphoma last June. Demand across those indications has Celgene expecting Revlimid's sales will total between $4.2 billion and $4.3 billion this year.

But Revlimid isn't the only drug succeeding for Celgene. Abraxane -- approved for breast cancer in 2005, non-small cell lung cancer in 2012 and pancreatic cancer this past September -- enjoyed 60% year-over-year sales growth on its way to $170 million in third-quarter sales.

The company also won FDA approval for Pomalyst as a treatment for multiple myeloma in February, which helped Pomalyst sales climb 35% year-over-year to $90 million in Q3. Across these three drugs and Celgene's other therapies, Vidaza and Thalomid, Celgene estimates that full-year sales will come in near $6.2 billion this year.

Yet, investors aren't overpaying relative to other biotechs
Amgen paid nearly 17 times sales to acquire Onyx Pharmaceuticals to get a hold of Onyx's oncology drug Kyprolis, which competes against Celgene in multiple myeloma. Despite that vote of confidence for the industry, Celgene is trading in line with other big biotechs like Regeneron (NASDAQ:REGN), Gilead Sciences (NASDAQ:GILD), and Biogen (NASDAQ:BIIB) at 11 times sales.

Similar to Celgene, all three of those companies have blockbuster drugs on their hands and have pipelines likely to produce significant sales in the future.

Regeneron's revenue totaled nearly $1.5 billion over the first nine months of 2013 thanks to Eylea, its treatment for age-related macular degeneration. Eylea saw U.S. sales grow 79% to $1 billion over the period. Regeneron's PCSK9 LDL cholesterol-lowering drug alirocumab and rheumatoid arthritis drug sarilumab are both in phase 3 and offer potential future revenue growth.

Gilead had total sales of $7.7 billion in the first nine months of 2013, most of which has come from its antiviral drugs, including its $3.6 billion a year AIDS drug Atripla. The company won one of the most highly anticipated FDA approvals in recent memory in December, when the FDA gave the nod to its Sovaldi for hepatitis C. Gilead also has high hopes for idelalisib, a drug under evaluation for leukemia and lymphoma.

Meanwhile, Biogen augmented its $2.8 billion a year multiple sclerosis drug Avonex by launching Tecfidera this past summer. Sales for that drug have already reached $286 million in the third quarter. Treatments for hemophilia, leukemia, and lymphoma are in the late stage of development and could drive future sales growth for Biogen.

Comparing these big biotechs to Celgene shows all three are valued similarly to or arguably more expensively than Celgene.

Analysts have increased estimates for Celgene's earnings per share to $7.3 for next year, roughly 20% more than this year. That gives Celgene a forward P/E ratio of 22, lower than Biogen, Gilead, and Regeneron. Celgene's P/E to growth ratio of 1.24 is also less than both Regeneron and Biogen.


Price to Sales

Price to Forward Earnings

Price/Earnings to Growth (PEG Ratio)

















Source: Yahoo! Finance.

Future growth may mean Celgene is even cheaper
Celgene doesn't think Revlimid's opportunity is limited to its currently approved indications. While Revlimid failed in a late stage leukemia trial in July , Celgene reported positive data in newly diagnosed multiple myeloma patients last summer and is studying the drug as a treatment for non-Hodgkins lymphoma.

In addition to Revlimid, Celgene is evaluating 25 unique compounds for 30 diseases across hundreds of ongoing studies. One of the most promising of those drug candidates is apremilast, which is in trials for a range of autoimmune diseases including psoriasis and psoriatic arthritis -- indications with significant demand and blockbuster existing treatments like AbbVie's Humira. Celgene filed for FDA approval of apremilast in psoriatic arthritis and an FDA decision is expected early in 2014.

Celgene has also taken stakes in emerging biotechs with promising therapies or delivery mechanisms, including OncoMed (NASDAQ:OMED). Onco's stem cell targeting oncology drug pipeline includes demcizumab. That drug is heading into mid stage trials for pancreatic, colorectal, non-small cell lung and ovarian cancer.

Celgene's other deals with young biotech companies include partnerships with Epizyme for its mixed lineage leukemia drug; blubird bio, which is working on reengineering T-cells into cancer killers; and Acetylon, which has an early stage myeloma prospect.

Fool-worthy final thoughts
Celgene's enthusiasm for expanding labels on its current drugs and reaping rewards from its collaborations with these emerging biotech companies, has the company projecting its sales will double to $12 billion by 2017. That heady forecast has the industry forecasting earnings per share could head north of $12 in 2016. If so, short-term sell-offs in Celgene's shares may provide long-term investors with an opportunity to build positions.

CELG EPS Estimates for Current and Next 3 Fiscal Years Chart

CELG EPS Estimates for Current and Next 3 Fiscal Years data by YCharts.

Another top stock you should be watching
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!

Todd Campbell has no position in any stocks mentioned.  Todd owns E.B. Capital Markets, LLC.  E.B. Capital's clients may or may not have shares in the companies mentioned.  Todd also owns Gundalow Advisors, LLC.  Gundalow's clients do not own shares in the companies mentioned. The Motley Fool recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information